Literature DB >> 15140513

Drug use by pregnant women and comparable non-pregnant women in The Netherlands with reference to the Australian classification system.

Eric Schirm1, Willemijn M Meijer, Hilde Tobi, Lolkje T W de Jong-van den Berg.   

Abstract

OBJECTIVE: To describe drug use in pregnancy, and compare drug use of pregnant women with non-pregnant women with respect to possible teratogenicity. STUDY
DESIGN: A cross-sectional study based on pharmacy records from 1997 to 2001 was performed. Pregnant women and matched non-pregnant women (same physician and age) were identified. Prescriptions were set against the Australian risk classification.
RESULTS: Thirty-five percent of all prescriptions for non-pregnant women were safe in pregnancy (Australian classification A), in 14% the risk was unknown (B1, B2), 49% were potentially harmful drugs (B3, C, D, X), and in 3% no classification was available. For pregnant women these figures were 86, 3, 10 and 2%, respectively. In non-pregnant women the highest percentages of prescriptions for unsafe drugs were for psycholeptics (99% not classified as safe), psychoanaleptics (100%), anti-inflammatory/antirheumetic products (100%), antihistamines (94%), antacids/anti-ulcer drugs (81%), antiepileptics (100%), beta-blockers (100%), systemic antimycotics (100%), antiprotozoals (97%), diuretics (100%) and immunosuppressives (100%). In pregnant women this pattern was comparable, except for antihistamines (22%) and antacids/anti-ulcer drugs (3%).
CONCLUSION: We conclude that many drugs used by non-pregnant women should be avoided in pregnancy, and that pregnant women indeed do so. However, for some drug groups the available safe alternatives are limited.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140513     DOI: 10.1016/j.ejogrb.2003.10.024

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  14 in total

1.  Drugs dispensed in primary care during pregnancy: a record-linkage analysis in Tayside, Scotland.

Authors:  Linda Irvine; Robert W V Flynn; Gillian Libby; Iain K Crombie; Josie M M Evans
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

2.  Prevalence and patterns of antidepressant drug use during pregnancy.

Authors:  Tessa Ververs; Hans Kaasenbrood; Gerard Visser; Fred Schobben; Lolkje de Jong-van den Berg; Toine Egberts
Journal:  Eur J Clin Pharmacol       Date:  2006-08-08       Impact factor: 2.953

3.  Application and feasibility of systemic lupus erythematosus reproductive health care quality indicators at a public urban rheumatology clinic.

Authors:  I Quinzanos; L Davis; A Keniston; A Nash; J Yazdany; R Fransen; J M Hirsh; J Zell
Journal:  Lupus       Date:  2014-09-29       Impact factor: 2.911

Review 4.  Prescription drug use during pregnancy in developed countries: a systematic review.

Authors:  Jamie R Daw; Gillian E Hanley; Devon L Greyson; Steven G Morgan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-07-20       Impact factor: 2.890

5.  Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations.

Authors:  Rachel A Charlton; John G Weil; Marianne C Cunnington; Sayantani Ray; Corinne S de Vries
Journal:  Drug Saf       Date:  2011-02-01       Impact factor: 5.606

6.  Randomized trial to improve prescribing safety during pregnancy.

Authors:  Marsha A Raebel; Nikki M Carroll; Julia A Kelleher; Elizabeth A Chester; Sally Berga; David J Magid
Journal:  J Am Med Inform Assoc       Date:  2007-04-25       Impact factor: 4.497

7.  Prescription of hazardous drugs during pregnancy.

Authors:  Heli Malm; Jaana Martikainen; Timo Klaukka; Pertti J Neuvonen
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  Assessing the information in the Summaries of Product Characteristics for the use of medicines in pregnancy and lactation.

Authors:  Blanca Arguello; Teresa M Salgado; Fernando Fernandez-Llimos
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

9.  Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002-2011: A Population-Based Cohort Study.

Authors:  Kate Smolina; Gillian E Hanley; Barbara Mintzes; Tim F Oberlander; Steve Morgan
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

10.  Prevalence and predictors of over-the-counter medication use among pregnant women: a cross-sectional study in the Netherlands.

Authors:  Gwenny Mpj Verstappen; Elise J Smolders; Janna M Munster; Jan G Aarnoudse; Eelko Hak
Journal:  BMC Public Health       Date:  2013-03-02       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.